



**Eisai Co., Ltd.**

**4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088 , Japan**

**Phone: 03- 3817-5120**

**Fax: 03- 3811-3077**

*Eisai is a Human Health Care Corporation striving for innovative solutions in prevention, cure and care for the health and well-being of people worldwide. We combine our talents to understand and meet the needs of patients and their families to enhance the quality of life.*

---

No. 08-49

**FOR IMMEDIATE RELEASE**

July 30, 2008

Eisai Co., Ltd.

**Eisai China Inc. Signs License Agreement in China  
for -Lipon 300 STADA for Diabetic Neuropathic Pain**

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that Eisai China Inc. (Headquarters: Suz

Contact:

Corporate Communications Department

Eisai Co., Ltd.

81-3-3817-5120

**<Notes to Editors>**

**About -Lipon 300 STADA**

**Product Name:** -Lipon 300 STADA®

**Generic name:** - lipoic acid

**Applied Indication:** Paresthesia associated with diabetic neuropathy

**Dosage and Administration:** The recommended dosage of -Lipon 300 STADA is 300 to 600mg (one to two ampoules) a day as - lipoic acid for two to four weeks. -Lipon 300 STADA can be administered by I.V., infusion, or I.M. I.V. should be by slow injection, with the rate not exceeding 50mg per minute (equivalent to 2mL injection). When administered by infusion, -Lipon 300 STADA, for afhoz097us2pv-2r